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Scientiﬁc advances are raising expectations that patient-tailored treatment will soon be available. The development of resulting
clinical approaches needs to be based on well-designed experimental and observational procedures that provide data to which
proper biostatistical analyses are applied. Gene expression microarray and related technology are rapidly evolving. It is providing
extremely large gene expression proﬁles containing many thousands of measurements. Choosing a subset from these gene
expression measurements to include in a gene expression signature is one of the many challenges needing to be met. Choice of this
signature depends on many factors, including the selection of patients in the training set. So the reliability and reproducibility of
the resultant prognostic gene signature needs to be evaluated, in such a way as to be relevant to the clinical setting. A relatively
straightforward approach is based on cross validation, with separate selection of genes at each iteration to avoid selection bias.
Withinthisapproachwedevelopedtwodiﬀerentmethods,onebasedonforwardselection,theotherongenesthatwerestatistically
signiﬁcant in all training blocks of data. We demonstrate our approach to gene signature evaluation with a well-known breast
cancer data set.
Copyright © 2009 Y. E. Pittelkow and S. R. Wilson. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
The era of personalised medicine is being widely heralded,
with claims including “all human illness can be studied by
microarray analysis, and the ultimate goal [] is to develop
eﬀective treatments or cures for every human disease by
2050”[1].Theﬁrststepistheselectionofpredictorsfromthe
many (often tens of) thousands of measurements that can be
made using modern microarray technology.
As is well known amongst statisticians, genes identiﬁed
from a microarray analysis as predictors of outcome, and
so included in a molecular signature, depend greatly on
the selection of patients in the training set. Hence it has
beenadvocatedthatvalidationbyrepeatedrandomsampling
(RRS) should be used [2]. RRS is advocated elsewhere, for
example for selecting genes for classiﬁcation [3]. The RRS
approach can quickly become extremely computer intensive.
Alternatively, the far less computer intensive method of 10-
fold cross-validation has been shown empirically, for two
microarray data sets, to perform very well when compared
with repeated random sampling [4].
K-fold cross-validation is a resampling method that is
widely used in practice for estimating performance of a
prediction rule (“signature”) when there is insuﬃcient data
to split the data into the ideal 3 parts: training, validation,
and testing. For microarray experiments where the number,
M, of measurements (say gene-expression values on an
Aﬀymetrix chip) is extremely large compared with the
number, s, of samples (chips), it is starting to become clear
thatsometraditionaldatastatisticalpracticesmaynotalways
be appropriate.
There is considerable confusion about the application of
cross-validationandmanyinvestigatorshavenotunderstood
the importance of signature selection at each of the K sepa-
rate steps [4]. If the signal-to-noise ratio of the underlying
function is relatively strong then the signature may not vary2 Journal of Biomedicine and Biotechnology
very much. However, if it is not strong, and this is very likely
when the number of measurements is very large compared
with the number of samples, then the signature may vary
appreciably; see [5, 6]. Further, it has been noted that “the
most striking ﬁnding when comparing the signiﬁcant lists
[from diﬀerent studies] is the virtually complete lack of
agreement in the included genes ... the present lack of
coherence [] warrants further examination” [7].
The reason for the diﬀerences could be attributed to
a number of factors, including methodology (model, algo-
rithm, gene selection, preprocessing steps such as normal-
isation, transformation, etc.), data (diﬀerent samples, het-
erogeneous samples, poor measurements, poor experimental
designs leading to the presence of confounders, etc.), and the
underlying biology (diﬀerent genes from the same pathway,
considered later). The fragility of a prediction model has
been demonstrated [8] by showing that published results
could not be replicated using the same data, when training
and tests sets were interchanged and the same algorithms
applied.
Here we consider a relatively large study [9] that
was used to predict distant metastasis of lymph-node-
negative primary breast cancer based on determination
of a single signature. The data are available in series
GSE2034 at the NCBI Genebank GEO. These data consist
of gene expression values from 286 Aﬀymetrix U133a
chips each with gene expression values for over 22000
“genes”. Of these patients, 209 were oestrogen receptor-
positive (ER+) and 77 patients were oestrogen receptor-
negative (ER
−). Brieﬂy, the samples were a subset of frozen
tumour samples from patients with lymph-node negative
breastcancerwhichhadbeensubmittedforsteroid-hormone
receptor measurement from an intake of 25 hospitals;
further details in [9]. Metastasis status was determined
fromfollow-upexaminationsorconﬁrmedfollowingpatient
report. The (statistical) sample selection was nonrandom
and the data show considerable variation in many known
breast cancer prognostic factors, such as therapy type, age,
menopausal status, tumour grade, and stage for exam-
ple. Data on these factors were not available on the
web.
In the following, the ER+ patient data are chosen for
illustrative purposes, noting that this selection also controls
some of the overall patient heterogeneity. Use of 10-fold
cross-validation is explored to determine those genes that
are included in molecular signatures (lists). In other words,
signature stability is evaluated, as is the variability of
prediction measures.
2. Methods
First, gene expression values were log transformed (base 2)
after zero values were set to 0.1.
Two methods, both of which correct for selection bias
[4], were developed and applied to these breast cancer data.
Before detailing the methods we outline the basic steps of K-
fold cross-validation:
(a) randomly divide the data into K separate and
approximately equal parts called validation sets;
(b) leave out one of the validation sets, then (b1)pe rf o rm
the analysis using the combined data of the remaining K-
1 parts (referred to as the “training set”) and, usually, (b2)
validate the analysis (that is often making prediction/s) on
the “validation set”;
(c) repeat (b) K times, so that following the (usual) b2
step each one of the (separate) K validation sets is used once
(e.g., for prediction/s).
For method (i), within each training set at step (b1),
we ﬁrst did an initial screening by applying a univariate
Cox proportional hazards regression model (Cox PHM) to
select those genes in each of the training sets that were
statistically signiﬁcant for metastasis-free survival. A (par-
tial) likelihood ratio test, comparing the partial likelihood
estimated for the gene to the null model, was used. Genes
were retained when the likelihood ratio test was statistically
signiﬁcant at level α1. Next, restricting attention to just
these retained genes, we used a Cox PHM with forward
selection to select amongst the genes available following the
initial gene selection. The selection was terminated when
the statistical signiﬁcance for inclusion into the Cox PHM,
using a log likelihood ratio test, was greater than level
α2.F o rs t e p( b 2), the resulting model was used to predict
relapse-free survival at 5 years on the validation data set.
To evaluate predictive performance, a binary outcome was
deﬁned [2], namely whether the predicted probability of
a patient was relapse-free, was greater than, or less than,
0.5. Then, three measures of predictive performance (also
called accuracy of classiﬁcation) were estimated, namely
the true positive fraction (TPF), also known as sensitivity,
the false positive fraction (FPF) and the proportion of
correctly predicted samples. Speciﬁcity is 1-FPF. In a clinical
setting, sensitivity and speciﬁcity are more relevant than the
proportion correctly predicted (i.e., 1 – classiﬁcation error)
that is often the measure reported in the bioinformatics
literature. It is straightforward to show that the proportion
of correctly predicted samples is a weighted average of
sensitivity and speciﬁcity. Note that the proportion correctly
predicted can be misleading if the outcome is rare or very
common.
Method (ii) followed method (i) except that instead
of forward selection we selected those genes which were
signiﬁcant at level α1 in all training sets. Then all these genes
were used in the signature with a multivariate Cox PHM
being ﬁtted at each iteration. The validation at step (b2)i n
the second iteration was as described for method (i). This
approach has been used successfully on data from proteomic
proﬁling to distinguish malignant pancreatic cancer from
benign disease [10].
There is no general rule for the value of K,a n dK = 1,
5, 10, and
√
s (where s is the sample size) have all been
suggested; the trade-oﬀ is between bias and variance [5].
Following Ambroise & McLachlan [4], we chose K = 10.
This choice seems to balance the trade-oﬀ between bias
with higher values of K and variability as observed for low
K values, particularly K = 1 (the so-called leave-one-one
cross validation). Note that any two 10-fold cross-validation
training sets have approximately 80% of the total sample in
common.Journal of Biomedicine and Biotechnology 3
Table 1: Annotation analysis of the signatures 1 to 10; the table entries show the number of genes found in each signature to include the
function shown in the ﬁrst column, with a blank indicating zero.
F u n c t i o n 1234567891 0
C e l l c y c l e 221 313
Cell Proliferation 1 2 1 1
D N A r e p a i r 1 111
Immune response 1 1 2 3 1 1
C e l l G r o w t h 121
T r a n s c r i p t i o n 331223211 2
Cell-cell signal 1 1 1
Development 2 1 2 1
ATP binding 2 2 3 23342 1
Nucleotide binding 3 4 3 1 14242
DNA binding 2 2 1 1 1
Cell adhesion 1 1 2 2 3 1 1
Golgi stack 1 1 1 1
K i n a s e a c t i v i t y 233121111 1
T r a n s f e r a s e a c t i v i t y 223 31121 1
Here the cross-validation was applied in stratiﬁed form,
so that approximately equal numbers of distant (i.e., beyond
5 years) metastases patients were included in the validation
sets.Wefoundthatoursubstantiveconclusionschangedlittle
if this restriction was relaxed.
The Cox proportional hazards model was chosen for
modelling metastasis free survival, t, because of censoring in
the data. The Cox PHM models the conditional hazard as the
product of a baseline hazard, λ0(t), and an exponential form
of a linear function of covariates, z,h e r el o g 2 gene expression
values, as follows:
λ(t|z) = λ0(t)exp

β
 z

. (1)
The assumption of proportional hazards was evaluated and
found adequate for a small number of signiﬁcant genes.
Known gene function was examined using a text search
on annotation available from the Aﬀymetrix web site. The
Rs o f t w a r e[ 11] with the package “survival” was used for
analysis.
3. Results
3.1. Method (i). The initial screening of genes at step (b1),
using a univariate Cox regression analyses, with α1 ≤ .001
identiﬁed from 210 to 342 genes in the 10 training sets.
Altogether across the 10 training sets, 675 unique genes were
found.
The 10 signatures built using a Cox PHM with forward
selection in each training set and with α2 ≤ .001, consisted
of 11 to 18 genes. Genes were generally uncorrelated within
each signature.
The 10 signatures have very few genes in common;
that is, the signatures are very unstable. For example, one
gene occurred in 6 signatures (the most common), 4 genes
occurred in 4 signatures and 8 genes in 3 signatures. Seventy
genes occurred only once. Also very few of the 60 genes in
Wang et al.’s [9] signature for the subset of ER+ patients
occurred in the 10 signatures. Three of the signatures
included no genes in common with the Wang signature and
the signature with the largest number of genes in common
had only four genes in common.
The discrepancies between the ten signatures might be
thought to be occurring because correlated genes in the
samepathway/sarebeingselected.Table 1 showsthenumber
of genes found in each signature with diﬀerent functional
classes. These classes are based on those in Wang et al. (Table
4) [9, 12]. Functional classes that were found in none or
only one signature are not shown. This analysis is not meant
to be deﬁnitive but to illustrate the lack of consistency in
apparent function between the signatures. We note that the
variation demonstrated here may reﬂect the complexity of
signalling processes in possibly many pathways, and/or the
presence of tumour subtypes [13] and/or the heterogeneity
in the sample.
Table 2 shows signature performance indices estimated
on the training sets. As is well known now, when the
performance is estimated on the same set as used to train
the signature, the performance is over optimistic (i.e., biased
[4]). Table 2 shows that each signature predicts distant
metastasis very well for the data on which they were trained,
even though the signatures were composed of a relatively
small number of genes (average 15). However, Table 3
shows that the performance is considerably worse when the
signature is used to predict metastasis-free status on the
validation set. The test error, estimated as the proportion
misclassiﬁed, using distant metastasis within 5 years as the
deﬁning mark, varies between 0.19 (= 1 − 0.810) and 0.55
(= 1 − 0.450). The average unbiased estimate of error
rate is 32.6%, while the biased estimate of error rate is
only 11.5%. The variance of the unbiased test error is
122.7.4 Journal of Biomedicine and Biotechnology
Table 2: Biased estimators of prediction performance for the ten
signatures estimated on the training sets.
Signature Prop. of true
positives
Prop. of false
positives
Prop. correctly
predicted
1 0.943 0.213 0.891
2 0.943 0.206 0.892
3 0.926 0.230 0.874
4 0.934 0.230 0.879
5 0.959 0.213 0.901
6 0.942 0.197 0.896
7 0.942 0.262 0.874
8 0.967 0.164 0.923
9 0.950 0.279 0.874
10 0.942 0.344 0.846
Average 0.945 0.234 0.885
Table 3: Unbiased estimators of prediction performance for the ten
signatures estimated on the validation sets.
Signature Prop. of true
positives
Prop. false
positives
Prop. correctly
predicted
1 0.750 0.714 0.579
2 1.000 0.800 0.778
3 0.769 0.714 0.600
4 0.786 0.714 0.619
5 0.929 0.429 0.810
6 0.857 0.571 0.714
7 0.929 0.714 0.714
8 0.538 0.714 0.450
9 0.857 0.571 0.714
10 0.857 0.429 0.762
Average 0.827 0.637 0.674
3.2. Method (ii). We demonstrate the second method using
2v a l u e so fα1 for the initial screening. With α1 ≤ .001, there
were 59 genes that were statistically signiﬁcant in all training
setsformetastasis-freesurvival,usingaunivariateCoxPHM.
To assess performance of this method we estimated the
Cox PHM using these 59 genes and predicted relapse-free
survival at 5 years in each corresponding validation set.
The true positive fractions (TPF) and false positive fractions
(FPF) are plotted on the left in Figure 1. The location of
the average pair (TPF, FPF) = (0.793 0.581) is shown. The
average TPF is slightly lower than for method (i) but so also
is the FPF which is desirable. Given the variability of the
estimates, these averages can be considered approximately
the same. The lower range of the FPF is less here than for
method (i), whereas the comparison of the FPF values in the
ﬁgureandwithcorrespondingcolumninTable 3 indicatesan
improvement over method (i). The average error rate from
the validation sets is 33.3%, which is similar to method (i),
but with variance 74.4 which is much lower.
When α1 ≤ .0001 was used for the initial gene selection,
14 genes were identiﬁed for inclusion in the signature. The
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∗
0
0.2
0.4
0.6
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1
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P
F
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Figure 1: Performance assessment for method (ii). The pairs (TPF,
FPF) estimated on the validation set are plotted in each graph. The
assessment for the 59 gene signature (α1 ≤ .001) is shown on the
upper and that for the 14 gene signature (α1 ≤ .0001) is shown on
the lower.
pairs (TPF, FPF) estimated on the validation set for this
signatureareplottedontherightof Figure 1.Thea v eragesof
TPFandFPFare0.896and0.548,respectivelywithassociated
variances 0.009 and 0.042. The average estimate of error rate
has decreased to 25.5%, with variance 50.0.
4. Discussion
Cross-validation is shown to be a useful tool to assess
performance and stability of molecular signatures used for
prediction from microarray data. Such an evaluation isJournal of Biomedicine and Biotechnology 5
necessary since the number of samples is small relative to the
number of measurements. Alternatives to cross-validation
for estimating predictive performance include the bootstrap
and repeated random sampling [3, 4]f o re x a m p l e ;b u t
for clarity in demonstrating instability of predictors, and
b e c a u s ei ti sm u c hl e s sc o m p u t e ri n t e n s i v e ,w ec o n c e n t r a t e d
here on cross-validation.
Within the cross-validation framework for developing
gene signatures, there are many choices, including which
initial screening approach to use and which method to
build the signature. Each choice may lead to diﬀerent genes
being included in a signature. The choices made in the
initial gene selection step here are somewhat arbitrary. Our
initial choice, to select genes with signiﬁcant (α1 ≤ 0.001)
association with breast cancer survival, was a strategy to
reduce the number of genes so that the potential number
was of the same order of magnitude as the number of
samples. This initial gene selection step is not required for
K-fold cross-validation in applications where the number of
variables is closer to sample size. This screening of genes has
interesting connections to the recent, independently derived,
proposal of iterative sure independence screening (ISIS) for
the linear model in ultrahigh dimensional feature space.
ISIS was motivated by the need to deal with problems of
large dimensionality for which accuracy of estimation and
computational cost are two concerns. For the linear model,
Fan and Lv [14] proposed reducing the dimensionality from
high to a moderate scale that is below the sample size, by
iteratively implementing a variable screening procedure and
ﬁtting the proposed model.
The presence of censored data indicates the use of
a survival model for building the signatures. Since the
Cox PHM has been found to be reasonably robust under
misspeciﬁcation [15], is well known in medical ﬁelds, and
was used by Wang et al. [9], it was chosen for developing
the signatures. This is preferable to the approach used by
Ein-Dor et al. [16] that was based on genes correlated with
survival, as “correlation” is not statistically appropriate in
this context.
In method (i), to train the signature on the training
data we used a stepwise procedure. It is well known that
such methods ﬁnd only a fraction of the models that
ﬁt the data well and can have the undesirable eﬀect of
over ﬁtting the data. However, eﬃcient screening of all
models is not computationally possible given the number
of genes (variables). Again, the use of a signiﬁcance level of
α1 ≤ 0.01 is somewhat arbitrary. In further analyses (not
reported) increasing α increased the number of genes and
the lack of agreement between the signatures. The use of
cross-validation helps to ascertain the extent of any over
ﬁtting but there is no known solution yet to ﬁnding the
“optimal” model in this setting. It is good practice to use
a number of approaches and to be satisﬁed only when
substantive conclusions are unaltered by the algorithm, and
basic assumptions are satisﬁed in so far as they can be tested.
The importance of implementing the same gene selection
rule/s for each of the training sets, in order to obtain
an unbiased estimate of the prediction error, is stressed.
Here there are two gene selection steps, and both need
to be implemented at each training step. This is necessary
because neither gene selection method is independent of the
prediction method.
Method (ii) is novel, with its incorporation of selection
based on variables that are common to all blocks using
a cross-validation type of approach. This would appear to
overcome the highly unstable list of genes identiﬁed as
predictors of prognosis that is found using either repeated
random sampling [3] or method (i), but needs to be further
evaluated on other data sets. Note that method (ii) is com-
parativelysimple,andcomputationallyfast.Currentresearch
concerns evaluation of the performance and stability of
signatures of both our variants of cross-validation with
the SIS-style approaches to screening before ﬁtting of the
model/s. Since thedata usedfortheselection of genesarenot
fully independent of the data used for validation, some bias
may exist in estimates of performance [17] and alternative
methods,includingtheuseof2-externalcross-validationwill
be investigated.
There are many ways in which cross-validation can be
developed so as to correct for selection bias [4], and we have
usedtwo.Anotherapproachthathasmanysimilaritiestoour
methods is to ﬁrst consider a range of the numbers of genes
to be used in the signature, say d0 to d1. Then within each
of the K training blocks, perform K-1-fold cross-validation,
and evaluate the signature for each value of d, selecting the
value that gives the best classiﬁcation rate for that block. The
value of d selected may vary between the K training blocks;
see[18]forfurtherdetails.Withtheadditionallayerofcross-
validation, as well as consideration of a range of values of d
within each training block, this is more computer-intensive
than our methods, although the associated variability may
well be less. Comparative performance of these approaches is
a future research project.
Itisimportanttodistinguishbetweentheuseofstatistical
models for prediction and for explanation [19]. In much of
the literature this distinction is blurred. Here we have been
concerned with choosing signatures for prediction. Some
investigators attempt to use a signature to build pathway/s
for explanatory purposes but such explanations are dubious
when the signatures can be very unstable.
Sample design is an important, but often overlooked,
consideration in microarray studies. It has been identiﬁed
as a key issue [20], and we emphasize that poor sample
design cannot be overcome with increased sample size.
Ideally the sample should be representative of the population
on which the signature is to be used. Again resampling
methods can help to highlight problems. Note that most of
the theoretical work underpinning justiﬁcation for method-
ologiesassumesthatthesamplesarerepresentative.Thereare
many unknowns about how non-homogeneity in the sample
aﬀects the performance of the predictors.
In this data set there were confounders, including age,
menopausalstatus,Tstage,Grade,andPRstatus,thatmaybe
important predictors, including their possible interaction/s
with particular genes, have not been considered here as
they are not publicly available. Although Wang et al. [9]
showed that these and other confounding factors were not
statistically signiﬁcant after adjusting for their gene signature6 Journal of Biomedicine and Biotechnology
inthetrainingset,theirinclusionmaybeusefulinpredicting
“new” samples. Their usefulness will arguably depend on
how well these-factors are “accounted for” by the genes
in the signature. The “best” signatures will in the end,
most probably, be developed by a combination of biological
expertise and computational algorithms.
Here we have demonstrated also the usefulness of using
false positive and false negative fractions for assessing the
performance of signatures. Particularly for medical applica-
tions, these measures of performance are more appropriate
for assessing relevance of test performance than the overall
classiﬁcation (or misclassiﬁcation) rate.
A promising approach has been to apply a protein-
network-based method [21] that, instead of identifying
markers as individual genes, considers them as subnetworks
as extracted from protein interaction databases. Unfortu-
nately the results suﬀer from selection bias. Two data sets
were used [9, 22], although one of the data sets [22] included
both node negative and node positive patients; just node
negative patients could have been selected for inclusion in
theanalyses.Itisimportanttocorrectforselectionbiaswhen
estimatingclassiﬁcationaccuracyfromuseofthesubnetwork
markers. As outlined above, to remove selection bias, the
subnetwork features should be identiﬁed at each step of the
cross-validation,not“identiﬁedusingallmicroarraysamples
before classiﬁcation” [21,p a g e4 ] .
5. Conclusion
We demonstrate the usefulness of the 10-fold cross-
validation framework for assessing performance of signa-
tures on a well-known Breast Cancer data set. Within this
approach we developed two diﬀerent methods, one based on
forward selection, the other on genes that were statistically
signiﬁcant in all training blocks of data.
This paper demonstrates a lack of agreement between
signatures estimated using a forward selection method on
randomly selected subsets of the same data. Our novel
method overcomes the instability of the forward selection
method.Itiscomputationallyfastandisshowntohavelower
test error variance and FPF.
The 10-fold cross-validation framework is a very useful
and less computer intensive method than some other re-
sampling methods. It allows estimation of unbiased misclas-
siﬁcation error as well as an assessment of the signature’s
sensitivity and speciﬁcity. Such evaluations are of utmost
importance especially when the number of samples is small
relative to the number of measurements.
The use of the pair of measurements, true positive frac-
tion (sensitivity) and false positive fraction (1-speciﬁcity),
provides a more clinically relevant evaluation of overall
performance than the single measure given by the correctly
predicted fraction (or its complement).
Although the hope of ﬁnding a single diagnostic tool is
laudable, it is still too early to be making any strong claims.
Given the complexity of human breast tumours, we agree
that it is unlikely that “robust and internationally agreed
signature gene lists will be accumulated in the near future”
[7].
Finally, we have as yet to fully understand the enormous
quantities of data that the rapidly evolving microarray
technologies are giving us. Moreover, “although the use of
gene-expression proﬁles in clinical practice is very appealing,
we should be very cautious ...”[ 23].
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